Tom Butler

Mr. Thomas Butler is a Chairman & Chief Executive Officer at Biomea Fusion, Inc. and a Managing Member at Point Sur Investors LLC.
Prior to forming the General Partner, from June 2013 through October 2015, Mr. Butler managed Investor Relations at Pharmacyclics Inc., where he helped grow the company from a market cap of $6.74B to over $21B, which included the execution of one of the largest biotech acquisitions to date.
Prior to Pharmacyclics, Inc., he spent 6 years as a medicinal chemist at Gilead Sciences Inc. engaging in novel drug design and drug development for HCV polymerase and protease inhibitors.
He received his undergraduate degree from The California State University, a Master's degree in Organic Chemistry from the University of California, Santa Barbara and an MBA from the University of California, Los Angeles.